

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**3DMed**

**思路迪**

**3D Medicines Inc.**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1244)**

**(1) DISCLOSEABLE TRANSACTION  
INVESTMENT IN A FUND AND SUBSCRIPTION OF WEALTH  
MANAGEMENT PRODUCTS;  
(2) SUPPLEMENTAL ANNOUNCEMENT  
IN RELATION TO THE 2022 ANNUAL REPORT; AND  
(3) CLARIFICATION OF INFORMATION ON THE ANNOUNCEMENTS**

**INVESTMENT IN A FUND**

On December 19, 2022, the Company subscribed for relevant participating shares attributable to a segregated portfolio of the Fund, at a subscription amount of US\$12,700,000 (equivalent to approximately RMB88.6 million) (the “**Investment**”).

**SUBSCRIPTION OF WEALTH MANAGEMENT PRODUCTS**

The Company subscribed for a wealth management product with CNCB in the amount of RMB20 million, and a wealth management product with CITIC International in the amount of HK\$50 million on October 24, 2022 and January 13, 2023, respectively (the “**CITIC Subscriptions**”).

On August 11, 2023, the Company subscribed for a wealth management product with UBS AG in the amount of HK\$180 million (the “**UBS Subscription**”).

**LISTING RULES IMPLICATIONS**

The subscription amount under each of the wealth management product with CNCB and with CITIC International, on a standalone basis, does not constitute a discloseable transaction under the Listing Rules. However, given that (i) CITIC International is majority-owned by CITIC International Financial Holdings, which in turn is wholly-owned by CNCB, and (ii) the nature of the wealth management product with CNCB and with CITIC International is similar, such transactions are required to be aggregated pursuant to Rule 14.22 of the Listing Rules.

As one of the applicable percentage ratios under Rule 14.07 of the Listing Rules in respect of each of the Investment, the CITIC Subscriptions and the UBS Subscription exceeds 5% but all applicable percentage ratios are less than 25%, each of the Investment, the CITIC Subscriptions and the UBS Subscription constitutes a discloseable transaction of the Company and is therefore subject to the reporting and announcement requirements but exempt from the shareholders' approval requirement under Chapter 14 of the Listing Rules.

Due to inadvertent oversight, the Investment, the CITIC Subscriptions and the UBS Subscription were not disclosed by the Company in accordance with Chapter 14 of the Listing Rules in a timely manner. Accordingly, remedial actions have been taken to prevent similar incidents from occurring in the future.

#### **SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE 2022 ANNUAL REPORT**

As at December 31, 2022, the Investment amounted to RMB88,505,193.54, the fair value of which is approximately 6.64% of the Company's total assets.

Save as disclosed in this announcement, all other information in the 2022 Annual Report remains unchanged.

#### **INVESTMENT IN A FUND**

On December 19, 2022, the Company subscribed for relevant participating shares attributable to a segregated portfolio of the Fund, at a subscription amount of US\$12,700,000 (equivalent to approximately RMB88.6 million). The source of funds for subscribing the Investment is the Company's internal resources. For the avoidance of doubt, the Investment was not funded by IPO proceeds.

The principal terms and redemption status of the Investment are as follows:

Date: December 19, 2022

Parties: (i) the Company as subscriber; and  
(ii) the Fund as issuer

As at the date of the Investment and the date of this announcement, to the best of the Directors' knowledge, information, and belief, having made all reasonable enquiries, the Fund, its segregated portfolio, the investment manager, the administrator and their respective ultimate beneficial owners are third parties independent of and not connected with the Company or its connected persons (as defined under the Listing Rules).

Investment amount: US\$12,700,000 (equivalent to approximately RMB88.6 million)

Basis for determining the investment amount:	The investment amount was determined through arm's length negotiations between the parties, taking into account the particulars of the Fund such as its terms, investment scope and risk exposure, the terms of the private placement memorandum and the commercial terms of similar funds in the market, and the amount of idle cash the Company wishes to utilise for treasury management purpose.
Target return rate:	The target return rate is 1.5% to 4.5% per annum.
Investment objectives and strategies:	The investment objective is to achieve long-term growth, irrespective of market direction or volatility. The segregated portfolio will seek to achieve the investment objective by investing in cash or cash equivalents, notes, portfolio funds and securities.
Term of the Investment:	From December 19, 2022 to redemption on demand
Redemption terms:	Redeemable anytime after five working days from the date of investment by submitting a redemption notice to the Fund, and the Fund shall deposit the redemption amount to the Company's bank account within five working days. Given that the Fund is of a principal-preservation nature, the total redemption amount will be greater than the investment amount paid.
Management fee:	The management fee payable by the Company is 1.8% of the net asset value of the participating shares attributable to the segregated portfolio of the Fund.
Redemption status:	Not yet redeemed as of the date of this announcement

## **INFORMATION ON THE PARTIES**

### **The Company**

The Company is principally engaged in the research and development of oncology therapies for cancer patients, especially those who require long-term care.

### **The Fund and its segregated portfolio**

The Future Vision Fund SPC is an exempted limited liability company registered as a segregated portfolio company with the Cayman Islands Monetary Authority. It is wholly owned by Mr. Xu Xiaodong.

Value Investment Fund SP, to which the Company subscribed, is a segregated portfolio of Future Vision Fund SPC established under the Cayman Islands laws that invests in cash or cash equivalents, notes, portfolio funds and securities.

## REASONS FOR AND BENEFITS OF THE INVESTMENT

The Company believes effective treasury functions include effective utilisation of its internal cash resources and making use of idle cash to increase interest income as part of normal daily treasury activities. In December 2022, in view of the ample cash balances exceeding the short-term working capital needs of the Group, as part of its treasury planning, the Company entered into the Investment for the purpose of making use of temporary idle cash for interest return in low risk investments/products with flexible redemption features. After taking into account the interest rate return and balancing the flexible redemption needs of the Group, the Company considered the Investment fit the needs of the Group as it involves principle-guaranteed fixed income products and have flexible redemption features. As such, the Company entered into the agreement in respect of the Investment.

In view of the above, the Directors (including the independent non-executive Directors) consider that the terms of the agreements of the Investment and the transactions contemplated thereunder are fair and reasonable, and are in the interests of the Company and the Shareholders as a whole.

## SUBSCRIPTION OF WEALTH MANAGEMENT PRODUCTS

The Company subscribed for a wealth management product with CNCB in the amount of RMB20.0 million, and a wealth management product with CITIC International in the amount of HK\$50.0 million on October 24, 2022 and January 13, 2023, respectively. On August 11, 2023, the Company subscribed for a wealth management product with UBS AG in the amount of HK\$180 million. The principal terms and redemption status of the subscription agreements are as follows:

### CITIC Subscriptions

#### *Subscription I*

Date of subscription:	October 24, 2022
Parties:	(1) Longteng Medicines, a wholly-owned subsidiary of the Company; and (2) CNCB.
Name of the wealth management product:	Win-win Zhixin Exchange Rate Linked RMB Structured Deposit Phase 12053 (共贏智信匯率掛鈎人民幣結構性存款 12053 期)
Type of product:	Close-ended principal guaranteed with variable return
Linked exchange rate:	The return of the deposit will be linked to the GBP/USD spot rate exchange rate (by referring to the Bloomberg BFIX GBP/USD Currency value as of 3:00 p.m. Tokyo time on a relevant date) (the “ <b>GBP/USD Reference Exchange Rate</b> ”).
Subscription amount:	RMB20.0 million (equivalent to approximately HK\$22.3 million)

Basis for determining the subscription amount:	The subscription amount and the terms in relation to the wealth management product were determined by the Company having taken into account (i) the then available surplus cash of the Group for treasury management purposes; (ii) the expected rate of return of the wealth management product; and (iii) the low risk level of the wealth management product.
Term of product:	98 days
Expected return:	<p>The expected return will be determined with reference to the change of the GBP/USD Reference Exchange Rate as of January 18, 2023 as compared to the GBP/USD Reference Exchange Rate as of October 25, 2022:</p> <ol style="list-style-type: none"> <li>a. If there is a decrease of greater than 5.5%, the annual return for the wealth management product shall be 3.05%;</li> <li>b. If there is a decrease of less than or equal to 5.5%, and an increase of no more than or equal to 15%, the annual return for the wealth management product shall be 2.65%; and</li> <li>c. If there is an increase of over 15%, the annual return for the wealth management product shall be 1.60%.</li> </ol>
Risk profile rating:	PR1 Rating (Conservative, green ranking) (the risk profile rating is an internal assessment of CNCB for reference only)
Early termination right:	<p>Unless otherwise agreed, the subscriber may not terminate the product prior to the maturity date or seek early redemption of the product.</p> <p>CNCB may unilaterally terminate the product ahead of its maturity date.</p>
Payment of principal and return:	All principal and returns accrued during the term of the product shall be settled on the maturity date (or any early termination date), or where such date is a public holiday, then to the next working day in the PRC.
Redemption status:	Fully redeemed on January 30, 2023

## ***Subscription II***

Date of subscription:	January 13, 2023
Parties:	(1) the Company; and (2) CITIC International.
Name of the wealth management product:	2-Week HKD Structured Deposit – Target Currency Linked
Type of product:	Principal not guaranteed with fixed return
Term of product:	January 13, 2023 to January 30, 2023
Linked exchange rate:	HKD/CNH as determined by CITIC International at 3:00 p.m. Tokyo time on January 30, 2023 by reference to the spot rate at 3:00 p.m. Tokyo time on January 30, 2023 published on Reuters (the “ <b>Final Reference Exchange Rate</b> ”).
Conversion Level:	1.1377
Subscription amount:	HK\$50.0 million
Basis for determining the subscription amount:	The subscription amount and the terms in relation to the wealth management product were determined by the Company having taken into account (i) the then available surplus cash of the Group for treasury management purposes; (ii) the expected rate of return of the wealth management product; and (iii) the low risk level of the wealth management product.
Interest rate:	3.000% per annum
Settlement amount:	The settlement amount to be received is either:  HKD50,069,863.01, if the Final Reference Exchange Rate is equal to or greater than the Conversion Level; or  CNH44,009,724.01, if the Final Reference Exchange Rate is less than the Conversion Level.
Early termination right:	The subscriber may not terminate the product prior to the maturity date or seek early redemption of the product.  CITIC International may unilaterally terminate the product ahead of its maturity date.
Payment of settlement amount:	All principal and returns accrued during the term of the product shall be settled on the maturity date, or where such date is a public holiday, then to the next working day in the PRC.
Redemption status:	Fully redeemed on January 30, 2023

## UBS Subscription

Date of subscription:	August 11, 2023
Parties:	(1) The Company; and (2) UBS AG.
Name of the wealth management product:	UBS Manage Premium
Type of product:	Principal not guaranteed
Subscription amount:	HK\$180 million
Basis for determining the subscription amount:	The subscription amount and the terms in relation to the wealth management product were determined by the Company having taken into account (i) the then available surplus cash of the Group for treasury management purposes; (ii) the expected rate of return of the wealth management product; and (iii) the low risk level of the wealth management product.
Term of investment period:	Not fixed, redeemable by UBS AG upon the request of the Company at any time.
Investment objective:	Preservation of assets, with very low volatility of asset value expected.
Investment portfolio:	The wealth management product will be invested in liquidity assets and bonds. The portfolio does not include equities, hedge funds, real estate or commodities.  As of August 11, 2023 and the date of this announcement, the portfolio is composed solely of U.S. Treasury bills.
Fee:	UBS AG will charge the Company a flat fee dependent upon the size of the managed portfolio and the applicable investment strategy. The flat fee includes commissions, transaction fees, spreads and costs for the investments, and custody fees.
Expected rate of investment return:	5.32% per annum
Redemption:	Redemption of funds or related instruments may be subject to payment of a redemption commission.  No minimum holding period and no penalty fee for redemption.
Redemption status:	HK\$54.6 million (approximately 30.33% of the subscription amount) was redeemed on August 31, 2023.

## **REASONS FOR AND BENEFITS OF THE CITIC SUBSCRIPTIONS AND THE UBS SUBSCRIPTION**

The CITIC Subscriptions and the UBS Subscription were carried out by the Company for treasury management purposes in order to maximize the utilization of its surplus cash received from its business operations, with a view to achieving balanced yields whilst maintaining high liquidity and a low level of risks. In addition, the CITIC Subscriptions and the UBS Subscription offer a better potential return to the Group when compared to the deposit interest rates generally offered by commercial banks in the PRC. Taking into account, among others, the low level of risks and the expected rates of return of the CITIC Subscriptions and the UBS Subscription, the Company considers that the CITIC Subscriptions and the UBS Subscription provide the Group with better returns than the returns on deposits generally offered by commercial banks and increase the Company's overall earnings in the long run. The funds required for the CITIC Subscriptions and the UBS Subscription were satisfied by the Group using the Group's internal resources (without utilizing any proceeds from the Global Offering).

In view of the above, the Directors (including the independent non-executive Directors) consider that the terms of the agreements of the CITIC Subscriptions and the UBS Subscription and the transactions contemplated thereunder are fair and reasonable, and are in the interests of the Company and the Shareholders as a whole.

## **INFORMATION ON THE PARTIES**

Longteng Medicines (Jiangsu) Co., Ltd.\* (龍騰藥業(江蘇)有限公司) is a limited liability company incorporated in the PRC on March 30, 2021. It is an indirect wholly-owned subsidiary of the Company, principally engaged in the manufacturing and trading.

CITIC International is incorporated and licensed in Hong Kong with business operations and presence spanning across Hong Kong, Macau, the PRC, the United States and Singapore. It is majority-owned by CITIC International Financial Holdings Limited, a company incorporated in Hong Kong, which in turn is wholly-owned by CNCB.

CNCB is a licensed bank incorporated under the laws of the PRC, engaged in, among other things, corporate finance, retail finance, financial market and other businesses. It is listed on the Stock Exchange (stock code: 00998) and the Shanghai Stock Exchange (stock code: 601998). To the best of the Directors' knowledge, information and belief after having made all reasonable enquiries, CITIC International, CNCB and their ultimate beneficial owners are third parties independent of the Company and its connected persons.

UBS AG is part of UBS Group AG which is a global financial services provider incorporated in Switzerland. To the best of the Directors' knowledge, information and belief having made all reasonable enquiries, (i) the ultimate beneficial owner of UBS AG is UBS Group AG, a company listed on both the SIX Swiss Exchange (SWX: UBSG) and the New York Stock Exchange (NYSE: UBS); and (ii) the Directors confirmed that UBS AG and its ultimate beneficial owner are third parties independent of and not connected with the Company or its connected persons (as defined under the Listing Rules).

## **LISTING RULES IMPLICATIONS**

The subscription amount under each of the wealth management products with CNCB and with CITIC International, on a standalone basis, does not constitute a discloseable transaction under the Listing Rules. However, given that (i) CITIC International is majority-owned by CITIC International Financial Holdings, which in turn is wholly-owned by CNCB, and (ii) the nature of the wealth management product with CNCB and with CITIC International is similar, such transactions are required to be aggregated pursuant to Rule 14.22 of the Listing Rules.

As one of the applicable percentage ratios under Rule 14.07 of the Listing Rules in respect of each of the Investment, the CITIC Subscriptions and the UBS Subscription exceeds 5% but all applicable percentage ratios are less than 25%, each of the Investment, the CITIC Subscriptions and the UBS Subscription constitutes a discloseable transaction of the Company and is therefore subject to the reporting and announcement requirements but exempt from the shareholders' approval requirement under Chapter 14 of the Listing Rules.

The Company acknowledges that it should issue an announcement as soon as possible under the Listing Rules for all notifiable transactions conducted by the Group, in compliance with Rule 14.34 of the Listing Rules. Regrettably, due to inadvertent oversight and particularly insensitivity and unfamiliarity of the management with the relevant requirements of the Listing Rules and implications of the Investment, the CITIC Subscriptions and the UBS Subscription thereunder, the Company did not make timely disclosure.

Upon revisiting the terms of the Investment, the CITIC Subscriptions and the UBS Subscription during the preparation of the interim results of the Group for the six months ended June 30, 2023 and seeking advice from the Board and professional advisers (including the Company's compliance adviser and legal advisers), the management realized its obligation to make timely disclosure with respect to the Investment, the CITIC Subscriptions and the UBS Subscription. Accordingly, the Company publishes this announcement to inform the Shareholders.

## **SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE 2022 ANNUAL REPORT**

Reference is made to the 2022 Annual Report. The Board would like to provide the following additional information pursuant to paragraph 32 (4A)(d) of Appendix 16 to the Listing Rules in relation to the significant investments of the Group held as of December 31, 2022:

During the year ended December 31, 2022, the Company subscribed for relevant participating shares attributable to a segregated portfolio of the Fund, at an investment amount of US\$12,700,000 (equivalent to approximately RMB88.6 million). The details of the Investment are as follows:

Name of the fund:	Future Vision Fund SPC
Name of the segregated portfolio of the fund:	Value Investment Fund SP, a segregated portfolio of Future Vision Fund SPC
Investment amount:	US\$12,700,000 (equivalent to approximately RMB88,577,420)
Investment objectives and strategies:	The Fund is of a principal-preservation nature. The investment objective is to achieve long-term growth, irrespective of market direction or volatility. The segregated portfolio will seek to achieve the investment objective by investing in cash or cash equivalents, national debt and other money market instruments.
Fair value as of December 31, 2022:	RMB88,505,193.54
Percentage to the Group's total asset as of December 31, 2022:	Approximately 6.64%

The Future Vision Fund SPC is an exempted limited liability company registered as a segregated portfolio company with the Cayman Islands Monetary Authority. To the best knowledge, information and belief of the Directors, having made all reasonable enquiries, the Future Vision Fund SPC, its segregated portfolio, the investment manager and their respective ultimate beneficial owners are third parties independent of and not connected with the Company or any connected persons of the Company.

The principal purpose of the Investment is to make use of temporary idle cash for low-risk investments with flexible redemption features. The Investment provides an opportunity for the Company to enhance returns by utilizing idle cash, without adversely affecting the Group's working capital.

The above additional information does not affect other information contained in the 2022 Annual Report and saved as disclosed above, all other information in the 2022 Annual Report remains unchanged.

## REMEDIAL ACTIONS

The Company deeply regrets its non-compliance with the Listing Rules, and would like to stress that the delay in compliance with the disclosure requirements under the Listing Rules was inadvertent and unintentional. The Company has no intention of withholding any information relating to the Investment, the CITIC Subscriptions and the UBS Subscription from the public. The Company takes this incident seriously and, in order to prevent similar incidents from occurring in the future, has implemented the following remedial actions:

1. in preparation for its interim results announcement for the six months ended June 30, 2023, the Company conducted a comprehensive review and self-examination of the subscription of funds and purchase of wealth management products, including but not limited to any such subscriptions or purchases since December 15, 2022 (the listing date of the Company), and publishes this announcement to inform its shareholders the Investment, the CITIC Subscriptions and the UBS Subscription that should have been disclosed but were not previously disclosed;
2. the Company's legal advisers have provided a training session to its finance and accounting personnel, responsible staff, and senior management to strengthen and reinforce their understanding of (i) inside information requirements under Part XIVA of the Securities and Futures Ordinance (Cap. 571); (ii) discloseable transaction requirements under Chapter 14 of the Listing Rules; and (iii) connected transaction requirements under Chapter 14A of the Listing Rules;
3. the Company will arrange regular quarterly trainings for its finance and accounting personnel to enhance their understanding of Listing Rules and the various disclosure obligations. These trainings will also cover topics such as risk management methodologies and internal protocols to report, approve and record transactions. Further, members of the Company's senior management will receive training every six months, while Directors will have annual training sessions. These targeted trainings aim to foster a culture of vigilance and accountability within the Company;
4. the Company has refined its internal guidelines for notifiable transactions under the Listing Rules with more details to ensure timely reporting and disclosure, in particular, the responsible staff must scrutinize any transaction that is (i) not of a revenue nature or not entered into in the ordinary and usual course of business of the Company; or (ii) entered into with connected persons of the Company, and escalate any potential notifiable transactions to the Company's management and (where necessary) the Board for assessment of implications under the Listing Rules before entering into such transactions; and
5. the Company will work closely with its internal legal advisers and, as and when appropriate, consult other professional advisers (including the Company's compliance adviser and legal advisers) before entering into any potential notifiable transaction. If necessary, the Company may also consult the Stock Exchange on the proper treatment of any proposed transaction.

## CLARIFICATION OF INFORMATION ON THE ANNOUNCEMENTS

The Company would like to clarify that due to inadvertent arithmetic error and typo, the information in the Company's announcements dated July 14, 2023 and August 25, 2023 in relation to the total net amount and balance of the proceeds from the Global Offering (including the proceeds from the partial exercise of the Over-allotment Option) was erroneously stated. Please refer to the below for the correct version.

Intended use of proceeds as stated in the Prospectus	Percentage to total amount %	Total net proceeds from the Global Offering (including the proceeds from the partial exercise of the Over-allotment Option) RMB'000	Utilized amount as at June 30, 2023 RMB'000	Unutilized amount as at June 30, 2023 RMB'000	Unutilized amount as at July 14, 2023 RMB'000	Expected time frame for unutilized amounts
(a) Research and development, regulatory filings and commercialization of our product and drug candidates:	90	209,635.1	71,196.6	138,438.5	132,096.2	Dec 2024
(i) 恩維達® envafolimab	55	128,110.3	47,125.6	80,984.7	75,672.2	Dec 2023
(ii) other drug candidates	25	58,232.0	20,824.7	37,407.2	36,377.4	Dec 2024
(iii) the construction of our in-house production facilities in Xuzhou, Jiangsu province and procurement of new machineries, instruments and equipment	10	23,292.8	3,246.2	20,046.6	20,046.6	Dec 2023
(b) General corporate and working capital purposes	10	23,292.8	22,391.5	901.3	–	Dec 2023
<b>Total</b>	<b>100</b>	<b>232,927.9</b>	<b>93,588.0</b>	<b>139,339.9</b>	<b>132,096.2</b>	

Save as disclosed in this announcement, all information set out in the aforementioned announcements remain unchanged.

“2022 Annual Report”	the annual report of the Company for 2022 published on April 28, 2023
“Board”	the board of Directors of the Company
“Company”	3D Medicines Inc., an exempted company incorporated with limited liability under the laws of the Cayman Islands and the shares of which are listed on the main board of the Stock Exchange (stock code: 1244)
“connected person(s)”	has the meaning ascribed to it under the Listing Rules
“CITIC International”	China CITIC Bank International Limited, a company incorporated in Hong Kong and an indirect non-wholly-owned subsidiary of CNCB
“CNCB”	China CITIC Bank Corporation Limited, a licensed bank incorporation in the PRC, the shares of which are listed on the Stock Exchange (stock code: 00998) and the Shanghai Stock Exchange (stock code: 601998)
“CNH”	offshore RMB
“Director(s)”	the directors of the Company, including all executive, non-executive and independent non-executive directors
“Fund”	the Future Vision Fund SPC, an exempted limited liability company registered as a segregated portfolio company with the Cayman Islands Monetary Authority
“Global Offering”	the offer of the shares of the Company for subscription as described in the prospectus of the Company dated November 29, 2022
“Group”	the Company and its subsidiaries
“Investment”	The subscription of relevant participating shares attributable to a segregated portfolio of the Fund, at a subscription amount of US\$12,700,000 (equivalent to approximately RMB88.6 million)
“IPO”	the initial public offering of the Shares on the Main Board of the Stock Exchange

“Listing Rules”	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited
“Longteng Medicines”	Longteng Medicines (Jiangsu) Co., Ltd.* (龍騰藥業(江蘇)有限公司), a limited liability company incorporated in the PRC on March 30, 2021, being an indirect wholly-owned subsidiary of the Company
“PRC”	the People’s Republic of China
“Prospectus”	the prospectus of the Company dated November 29, 2022
“RMB”	Renminbi, the lawful currency of the PRC
“Shareholders”	the shareholders of the Company
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“UBS Subscription”	the subscription of the wealth management product with UBS AG in the amount of HK\$180 million
“UBS AG”	UBS AG is incorporated in Switzerland with limited liability and the investment account of the Company in UBS AG is acting through its local branch in Hong Kong. The Hong Kong branch is authorized and regulated by the Hong Kong Monetary Authority.
“%”	per cent

By order of the Board  
**3D Medicines Inc.**  
**Dr. Gong Zhaolong**  
*Chairman of the Board*

Hong Kong  
September 25, 2023

*As at the date of this announcement, the Board of Directors of the Company comprises Dr. GONG Zhaolong as executive Director, Mr. ZHU Pai, Mr. ZHOU Feng and Ms. CHEN Yawen as non-executive Directors, and Dr. LI Jin, Dr. LIN Tat Pang and Mr. LIU Xinguang as independent non-executive Directors.*